Mustafa KULAKSIZOĞLU, Mustafa CAN, İlker ÇORDAN, Muhammet KOCABAŞ, Melia KARAKÖSE, Hatice ÇALIŞKAN BURGUCU, Feridun KARAKURT

Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population

Background/aim: The presence of comorbidities in patients with acromegaly causes an increase in morbidity and/or mortality and a decrease in quality of life. In this study, we aimed to investigate the demographic, clinical and laboratory features, prevalence of acromegaly-related comorbidities, and factors associated with these comorbidities in patients with acromegaly. Materials and methods: In the study, 96 patients who were followed up with the diagnosis of acromegaly were included. Clinical, laboratory and imaging features, and accompanying comorbidities of the patients were recorded from the patient files. Results: Of the patients included in the study, 63 (65.6%) were female and 33 (34.4%) were male. The mean age of diagnosis was 42.61± 12.08, and the mean follow-up period was 9.97 ± 7.26 years. Median insulin-like growth factor 1 level was 238.16 ng/mL (30.5–820), median growth hormone level was 2.05 ug/L (0.1–29.4). A total of 60 (62.5%) of the patients were in the well-controlled group, and 36 (37.5%) had active disease at the time of inclusion. Diabetes mellitus (DM) was detected in 30 (31.3%) patients, prediabetes in 19 (28.8%) patients, hypertriglyceridemia in 38 (42.2%) patients, hypertension (HT) in 41 (42.7%) patients, cardiovascular disease in 5 (5.2%) patients, malignancy in 9 (9.4%) patients, obstructive sleep apnea syndrome in 8 (8.3%) patients, carpal tunnel syndrome in 11 (11.5%) patients, arthropathy in 5 (5.2%) patients, hearing loss in 7 (7.3%) patients, thyroid nodule in 56 (67.5%) patients, thyroid cancer in 4 (4.2%) patients, colonic polyp in 19 (38.8%) patients. Conclusion: In this study, we revealed that the most common comorbidities in acromegaly patients in the Turkish population are thyroid nodules, low high-density lipoprotein (HDL cholesterol (HDL-C) level, hypertriglyceridemia, HT, colonic polyps, DM, and prediabetes, and female sex and age at diagnosis are the most important factors associated with comorbidities.Key words: Acromegaly, comorbidity, growth hormone, insulin-like growth factor 1

PDF

___

1. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 2011; 14 (3): 284-294. doi: 10.1007/ s11102-011-0310-7
2. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006; 355 (24): 2558-2573. doi: 10.1056/ NEJMra062453
3. Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocrine Connections 2014; 3 (2): 93-98. doi: 10.1530/EC-14-0021
4. Kreze A, Kreze-Spirova E, Mikulecky M. Risk factors for glucose intolerance in active acromegaly. Brazilian Journal of Medical and Biological Research 2001; 34 (11): 1429-1433. doi: 10.1590/s0100-879x2001001100009
5. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing’s disease. Acta Medica Austriaca 2000; 27 (1): 27-31. doi: 10.1046/j.1563-2571.2000.200106.x
6. Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF et al. The metabolic profile in active acromegaly is sex-specific. Journal of Clinical Endocrinology and Metabolism 2013; 98 (1): E51-59. doi: 10.1210/jc.2012-2896
7. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009; 30 (2): 152-177. doi: 10.1210/er.2008-0027
8. Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001; 4 (4): 239-249. doi: 10.1023/a:1020798430884
9. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P et al. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology (Oxf) 2001; 54 (2): 189- 195. doi: 10.1046/j.1365-2265.2001.01206.x
10. Ramos-Leví AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Endocrine 2017; 55 (2): 346-359. doi: 10.1007/s12020-016- 1191-3
11. Harrison BD, Millhouse KA, Harrington M, Nabarro JD. Lung function in acromegaly. Quarterly Journal of Medicine 1978; 47 (188): 517-532.
12. Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. European Journal of Endocrinology 2008; 159 (5): 533-540. doi: 10.1530/EJE-08-0442
13. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363 (9418): 1346-1353. doi: 10.1016/ S0140-6736(04)16044-3
14. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002; 13 (5): 395-400. doi: 10.1023/a:1015713732717
15. Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocrine Journal 2008; 55 (1): 67-71. doi: 10.1507/endocrj.k07e-010
16. Jenkins PJ, Sohaib SA, Akker S, Phillips RR, Spillane K et al. The pathology of median neuropathy in acromegaly. Annals of Internal Medicine 2000; 133 (3): 197-201. doi: 10.7326/0003- 4819-133-3-200008010-00011
17. Oktayoglu P, Nas K, Kilinç F, Tasdemir N, Bozkurt M et al. Assessment of the presence of carpal tunnel syndrome in patients with diabetes mellitus, hypothyroidism and acromegaly. Journal of Clinical and Diagnostic Research 2015; 9 (6): OC14-18. doi: 10.7860/JCDR/2015/13149.6101
18. Killinger Z, Payer J, Lazúrová I, Imrich R, Homérová Z et al. Arthropathy in acromegaly. Rheumatic Disease Clinics of North America 2010; 36 (4): 713-720. doi: 10.1016/j. rdc.2010.09.004
19. Kropf LL, Madeira M, Neto LV, Gadelha MR, de Farias ML. Functional evaluation of the joints in acromegalic patients and associated factors. Clinical Rheumatology 2013; 32 (7): 991- 998. doi: 10.1007/s10067-013-2219-1
20. Aydin K, Ozturk B, Turkyilmaz MD, Dagdelen S, Ozgen B et al. Functional and structural evaluation of hearing in acromegaly. Clinical Endocrinology (Oxf) 2012; 76 (3): 415- 419. doi: 10.1111/j.1365-2265.2011.04209.x
21. Wolinski K, Czarnywojtek A, Ruchala M. Risk of nodular thyroid disease and thyroid cancer in patients with acromegaly—meta-analysis and systematic review. PLoS One 2014; 9 (2): e88787. doi: 10.1371/journal.pone.0088787
22. Herrmann BL, Baumann H, Janssen OE, Görges R, Schmid KW et al. Impact of disease activity on thyroid disease in patients with acromegaly: basal evaluation and follow-up. Experimental and Clinical Endocrinology and Diabetes 2004; 112 (5): 225-230. doi: 10.1055/s-2004-817967
23. Pollack MN, Perdui JF, Mangolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters 1987; 38 (1-2): 223-230. doi: 10.1016/0304-3835(87)90218-7
24. Murphy LJ, Bill GI, Friesen HG. GH stimulates sequential induction of c-myc and insulin like growth factor—1 expression in vivo. Endocrinology 1987; 120 (5): 1806-1812. doi: 10.1210/ endo-120-5-1806
25. Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R et al. Colonoscopic screening and follow-up in patients with acromegaly: A multicenter study in Italy. Journal of Clinical Endocrinology and Metabolism 2005; 90 (1): 84-90. doi: 10.1210/jc.2004-0240